Alnylam Pharmaceuticals Inc (ALNY)
Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y
ALNY reports better-than-expected first-quarter results as both earnings and revenues beat estimates, driven by higher product sales.
Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates
Alnylam Pharmaceuticals (ALNY) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.16 per share a year ago.
Seeking Clues to Alnylam (ALNY) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Evaluate the expected performance of Alnylam (ALNY) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q1 Earnings Expected to Decline
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last?
Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock
The U.S. Food and Drug Administration on Thursday approved Alnylam Pharmaceuticals Inc.'s ALNY supplemental application for Amvuttra (vutrisiran).
Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains?
Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster
Alnylam Pharmaceuticals has secured FDA approval for Amvuttra in ATTR-CM, opening the door to potential revenue of over $6B. The company's strong R&D pipeline, including promising candidates like zilebesiran, supports long-term growth and will reduce its heavy near-term reliance on the TTR franchise. Amvuttra is likely to see strong initial adoption in ATTR-CM patients who've progressed on stabilizers, but greater first-line use and switchovers could drive the upside.
Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy
ALNY secures FDA approval for an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.
Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps
The U.S. Food and Drug Administration on Thursday approved Alnylam Pharmaceuticals Inc.'s ALNY supplemental application for Amvuttra (vutrisiran) in adults with cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, or ATTR-CM, to reduce cardiovascular mortality, cardiovascular hospitalizations, and urgent heart failure visits.
Alnylam shares rise on expanded heart drug approval
Alnylam Pharmaceuticals' shares rose about 7% before the bell on Friday following U.S. approval for its drug for a rare and deadly heart disease, securing an entry into a market dominated by Pfizer's blockbuster Vyndaqel.
